Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CIBC Maintains Neutral on Tilray, Lowers Price Target to $12

CIBC analyst John Zamparo maintains Tilray (NASDAQ:TLRY) with a Neutral and lowers the price target from $14 to $12.

byBenzinga Newsdesk

October 8, 2021

1 minute read

CIBC analyst John Zamparo maintains Tilray (NASDAQ:TLRY) with a Neutral and lowers the price target from $14 to $12.

Here’s How Much You Would Have Made Owning Tyson Foods Stock In The Last 15 Years

By Benzinga Insights

Today, 2:02 AM

Tyson Foods (NYSE:TSN) has outperformed the market over the past 15 years by 3.68% on an annualized basis…

TSN

Morgan Stanley Maintains Equal-Weight on Goldman Sachs Group, Lowers Price Target to $356

By Benzinga Newsdesk

Today, 2:02 AM

Morgan Stanley analyst Betsy Graseck maintains Goldman Sachs Group (NYSE:GS) with a Equal-Weight and lowers the price target from $384 to $356.

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

By Lisa Levin

Today, 2:02 AM

Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero Therapeutics shares rose 7.3% to $2.37 on Friday.

ACN

Analyst Ratings

Expert Ratings For Intel

By Benzinga Insights

Today, 2:02 AM

Analysts have provided the following ratings for Intel (NASDAQ:INTC) within the last quarter:

INTC

CIBC Maintains Neutral on Tilray, Lowers Price Target to $12

Related Posts

Here’s How Much You Would Have Made Owning Tyson Foods Stock In The Last 15 Years

Morgan Stanley Maintains Equal-Weight on Goldman Sachs Group, Lowers Price Target to $356

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

Expert Ratings For Intel